Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | F3 | P13726 | 3/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765657 | 0.86 | F2 (0.36) | F2MAPK1F3TRPV1NAMPT | |
| SCHEMBL30765880 | 0.85 | F3 (0.36) | F2F3 | |
| SCHEMBL30765486 | 0.84 | NTRK1 (0.33) | — | |
| SCHEMBL30765435 | 0.83 | F2 (0.36) | F2MAPK1F3NAMPTTSHR | |
| SCHEMBL30765827 | 0.83 | AKT1 (0.36) | TSHR | |
| SCHEMBL30765713 | 0.83 | AKT1 (0.36) | TSHR | |
| SCHEMBL30765553 | 0.82 | MAPK1 (0.37) | F2MAPK1F3NAMPT | |
| SCHEMBL30765646 | 0.80 | MAPK1 (0.38) | F2MAPK1F3NAMPT | |
| SCHEMBL30766040 | 0.79 | F2 (0.36) | F2MAPK1F3TRPV1NAMPT | |
| SCHEMBL30766059 | 0.79 | ALDH1A1 (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |